(دەزگای زەکاتی زانست سیمینارێکی پەروەردەیی پێشکەش کرد لە قوتابخانەی بنەڕەتی ژووان لە شارۆچکەی بازیان)
On 4th of February, the World Cancer Day, Asia International hospital held a symposium for all universities around the region to participate in presenting latest research findings and accomplishments four policy actions to reduce preventable cancers caused. The director of Cihan University Sulaimaniya Research Center (CUSRC) Assist. Prof. Dr. Fakher Karim Rahim, gave a presentation about “The Utility of the Oncotype DX Test for prognosis and recurrence of various Cancers”
Genomic tests analyze a sample of a cancer tumor to see how active certain genes are. The activity level of these genes affects the behavior of the cancer, including how likely it is to grow and spread. Genomic tests are used to help make decisions about whether more treatments after surgery would be beneficial. Oncotype Dx test is a laboratory test that is used to help predict whether breast cancer will spread to other parts of the body or come back. The test looks at the activity of 21 different genes in breast cancer tissue of women who have early-stage invasive breast cancer that is estrogen receptor positive and has not spread to the lymph nodes or has spread to 3 or fewer lymph nodes. If the test shows that there is a high risk that the cancer will spread or come back, treatment with anticancer drugs may be needed. Also called 21-gene signature. The results of the Oncotype DX Breast Recurrence Score Test, combined with other features of the cancer, can help you make a more informed decision about whether or not to have chemotherapy to treat early-stage, hormone-receptor-positive, HER2-negative breast cancer.
Related posts
